# W1 — Market & Path Analysis: Ranking Career Functions for the candidate's Re-Entry (2026)

> Worker: W1 (Market & Path Analyst) · Method: Research skill, Deep Investigation mode, 5 parallel multi-source agents, URL-verified · Date: 2026-07-02
> Every claim confidence-tagged `[HIGH]/[MED]/[LOW]`. Salary-aggregator figures (Glassdoor/PayScale/ZipRecruiter/Salary.com) are self-reported and noisy — tagged `[MED]` unless directly fetched. Personal details were kept out of all web queries.

---

## Executive verdict (read this first)

**ClinOps does NOT win for her.** The single best-fit re-entry function is **Regulatory Operations / Veeva RIM–Submissions** (leading into Regulatory Affairs), with **Quality Systems / Process Improvement** a very close second and the strongest match to her #1 energizer. Her **own current lane — Clinical Supply Chain — is the warmest, fastest re-entry** and belongs in the plan as the immediate paycheck / bridge, but its no-management ceiling is lower. ClinOps (as an entry function) is beaten on three of her hard constraints: entry comp, no-car/WLB, and speed-to-$150k.

The reason Reg Ops wins is narrow and specific: **it is the only function where her existing skills ARE the core job requirement, not adjacent to it** — Veeva Vault Author-level + document control + TMF + GxP + (per her résumé) *already routing IP labels with Regulatory Affairs*. She is also **RAC-certification-eligible today** through her QA years. Everywhere else she is transferring in; here she is already 70% qualified.

---

## Macro backdrop — is the 2023–24 downturn recovering? (2026)

- **Recovering, but bifurcated and not a boom.** Biopharma layoffs are easing sharply: **17 companies announced layoffs in Q2 2026 vs 33 in Q1 2026, and 64/62 in Q2/Q3 2025** — a sustained ~50% QoQ decline. `[HIGH]` (Fierce Biotech tracker)
- **First YoY job-posting growth in ~4 years:** active postings **+5% YoY (Feb 2026), +21% MoM**; R&D employment at a record high. `[HIGH]`
- **The catch — it's late-stage vs early-stage:** large sponsors and CROs are hiring; **early-stage/seed startups are still frozen** (IPO window shut). The **Bay Area is the hub most exposed to the early-stage freeze** → target established mid/large employers, CROs, and remote roles, not startups. `[HIGH]`
- **Two structural headwinds she must steer around:** (1) **Offshoring to India now includes *core* clinical ops, PV, data management, biostatistics** (~60% cost savings; Parexel +2,000 India hires) — pressures onshore *entry/coordinator* rungs. `[HIGH]` (2) **AI is automating the rote entry layer** — case processing, junior data management, junior CRA authorship → shifting from "doing" to "reviewing." `[MED-HIGH]` **Implication: aim past rote-entry seats toward judgment/coordination/specialist work, which is AI-complemented, not AI-replaced.**
- **Contract / temp-to-hire is healthy and is the best re-entry vector for her 2.5-yr gap** — explicitly used in life sciences as "try-before-you-buy," gap-tolerant. `[HIGH]` She is open to contract → use it.

---

## 1. Ranked table (best-fit first)

| # | Function (on-ramp title) | Demand '26 | Entry feasibility for her | Entry comp (Bay Area / natl) | Ladder to ~$150k on **IC** track? | Fit (1–5) | Notes |
|---|---|---|---|---|---|---|---|
| **1** | **Regulatory Operations / Veeva RIM–Submissions Specialist** → RA Specialist → **Principal RA Specialist** | Specialist-scarce in a soft market; ~120 live Veeva RIM reqs; reg work is legally-required = recession-resilient `[MED-HIGH]` | **Highest.** Veeva Author-level + doc control + TMF + GxP map 1:1; **RAC-eligible now** via QA yrs; gap = currency refresh not qualification `[HIGH]` | ~$98k+ SF Assoc / **$85–95k natl-remote** `[MED]` | **Yes, clean** — Sr Spec $137–147k, **Principal RA Spec (IC) $133–177k**, no reports `[HIGH]` | **5** | Team-embedded ("air-traffic-control") → **low isolation**; remote-heavy; crunch = cyclical filing windows |
| **2** | **Quality Systems / Process Improvement (CAPA / CI, *systems* track)** → QA/Quality Systems Specialist → **Principal/Staff Specialist** | QA/CI talent-short; eQMS + risk-based CAPA named top-demand skills (one source shows general-QA oversupplied — `[CONFLICT]`, but systems/CI tighter) `[MED]` | **Warm** — her doc-control + GxP + QA is the exact target profile; re-enter at Specialist II; CI/OpEx pivot needs Six Sigma + project evidence `[MED]` | ~$99k QA Specialist `[MED]` | **Yes, cleanest** — **Principal/Staff Specialist $150–190k**, true no-mgmt dual-track `[MED]` | **4.5** | **Best match to her #1 energizer (process improvement).** Audit crunch is real but **avoidable** by choosing *systems/CI* titles over batch-release/audit-host |
| **3** | **Clinical Supply Chain / CMC / IP (her lane, leveled up)** → Sr Clinical Supply Specialist / Assoc II | Stabilizing; was **insulated vs discovery** in the downturn; reshoring tailwind; more contract/fractional `[MED]` | **Warmest / fastest** — same lane; re-enter at Sr Assoc / Specialist II, **not a reset** `[MED]` | **$85–95k realistic, Bay Area top of band** `[HIGH]` | **Partial** — clean IC caps ~$105–120k; **$150k needs the (often light-mgmt) Manager rung** `[MED]` | **4** | Process-improvement content strong; crunch is event-driven (start-up/label windows), not chronic; **on-site/hybrid → transit-sensitive** (flag → W4) |
| **4** | **Clinical Data Management** → Clinical Data Associate/Coordinator → **Principal CDM** | Market growing (~11.8% CAGR, ~8k postings) but **headcount/trial flattening from automation**; CRO/India-weighted `[MED]` | **Strong match** — GCP/Veeva/TMF/21CFR11 transfer; reframe Vault-TMF → **Vault CDMS**; +CCDA cert `[HIGH]` | **$75–95k Bay Area** `[MED]` | **Yes** — **Principal CDM $147k verified (IC)** `[HIGH]` | **4** | CDM *proper* = reasoning ("why is this value implausible") = her "why/what-observed" interest; **but entry tier has rote data entry + AI exposure + database-lock crunch** |
| **5** | **Clinical Project Coordination → Project/Program Manager (IC)** → Clinical Project Coordinator / PMO Analyst | *Destination* (Clinical PM/Program Mgr) strong-demand; **on-ramp (coordinator) crowded + rote + most AI/offshore-exposed** `[MED]` | Feeds naturally from TMF/start-up/supply; **skip the generic-coordinator floor**; use contract to bridge gap `[MED]` | Generic coord < floor; **Bay Area specialist band $85–95k** `[MED]` | **Yes, clean** — Program Mgr (projects-not-people) ~$158k pharma; **PMP = +20–24%** `[MED-HIGH]` | **3.5** | **Lowest isolation (people-dense) — strong match**; but cyclical crunch (locks/start-up/audits); better as a **3–5 yr destination** than the entry |
| **6** | **Clinical Operations — Study Start-Up (SSU) Specialist** | CRO-resilient; SSU actively hiring `[MED]` | **Tight fit** — her *study-start-up support* + TMF + reg-doc + GxP is a direct match `[MED]` | **$70–90k** `[MED]` | Weak — via SSU Lead / Mgr; slower `[MED]` | **3.5** | Good **bridge** role; office/remote, low travel; keep as a ClinOps entry point *if* Reg Ops/Quality don't land first |
| 7 | **Clinical Operations — In-house / Remote CRA** | Remote CRA reqs plentiful; ~50% of new CRA reqs are remote/flex `[MED]` | **Credible reach** (Veeva/TMF/SSU = monitoring-adjacent); gap + no prior "CRA" title are the obstacles `[MED]` | **$60–80k** `[MED]` | Via Sr CRA III (~$130–150k, ~6–10 yr) `[MED]` | **3** | Solves no-car/WLB vs field CRA; **remote-solo isolation risk** (her top avoid) |
| 8 | **Medical / Regulatory Writing** → Medical Writing Assoc / Jr Regulatory Writer | Structural talent shortage; remote-heavy; reg-writing highest-paid writing niche `[MED]` | **Harder entry** — wants drafting *portfolio* (CSR/protocol), not just doc control; her SOP authoring helps but isn't enough `[MED]` | ~$80k natl `[MED]` | **Yes, clean** — Sr/**Principal Medical Writer $166–185k (IC)**; reg-writing mean ~$166k `[HIGH]` | **3** | **Best cognitive fit** (interpret protocol "why" + data "what-observed") **BUT often solo/remote → ISOLATION TRAP = her #1 avoid.** Only viable in a *team* CRO/in-house group |
| 9 | **Pharmacovigilance / Drug Safety** → Drug Safety Associate | High demand but **entry rung is the MOST AI-exposed** (65–80% case-processing automation) `[HIGH]` | **Weakest match** — favors pharmacy/nursing + Argus/MedDRA she lacks; GxP only as context `[MED]` | $45–75k `[MED]` | Only via **PV Scientist** science track; case-processing plateaus `[MED]` | **2.5** | Rote entry tier + continuous ICSR-clock deadline pressure; **not recommended** except as a fallback |
| — | **Clinical Operations — Field (traveling) CRA** | Candidate-tight for experienced `[MED]` | **Ruled out** | $55–70k entry | Sr CRA III $100–150k is the ladder engine | **1.5** | **Disqualified: no car** (field monitoring assumes driving) **+ 28–32% burnout turnover** — collides with WLB #1 `[HIGH]` |

---

## 2. Top recommended paths (why each fits *her* specifically)

### PATH A (PRIMARY) — Regulatory Operations / Veeva RIM–Submissions → Regulatory Affairs Specialist → Principal RA Specialist
This is the highest-probability, best-aligned re-entry in the whole set, and it wins on the exact axes she ranked. **Her most valuable asset is Veeva Vault Author-level competence, and Reg Ops/RIM is where that skill is the core requirement, not a nice-to-have** — mid-2026 had ~120 live "Veeva Vault RIM" reqs, many explicitly remote, screening for exactly "regulatory writing, strong document control, eTMF/RIM, stakeholder communication." `[HIGH]` Her résumé already shows her *designing, routing and approving IP labels in collaboration with Regulatory Affairs* — she has literally done proto-regulatory work. She is **RAC-eligible today** (RAPS counts her QA years). `[HIGH]` It clears every hard constraint: entry comp meets her $85–95k floor (SF Associate skews ~$98k+); the **IC ladder reaches $150k without managing anyone** (Principal RA Specialist $133–177k); the role is cross-functional and team-embedded, which **directly answers her hatred of isolation**; and it's **remote-friendly**, solving the no-car problem. The one honest caveat is **cyclical crunch around filing deadlines** (IND/NDA/BLA) — periodic, not constant. Net: her gap is a *currency refresh*, not a qualification deficit — the single strongest re-entry story she has.

### PATH B (CO-PRIMARY / best energizer-fit) — Quality Systems / Process Improvement (CAPA · CI · *systems* track) → Principal/Staff Specialist
If Path A is the best *feasibility* play, this is the best *fit-to-what-lights-her-up* play — **process improvement is her #1 ranked energizer, and her résumé is a trail of it** ("proposed SOP revisions to improve efficiency," "initiated/expanded trackable metrics," "authored the original Inventory Control SOP"). Quality *systems* / CAPA-effectiveness / deviation-trending / DMAIC is that instinct as a full-time job, and it offers the **cleanest no-management IC ladder to $150k in this entire report** (Principal/Staff Specialist $150–190k on a genuine dual-track). `[MED]` It's a talent-short market and the systems/eQMS sub-roles are the most remote-friendly corner of quality. **Crucial nuance that also corrects one of her assumptions:** she believes audit/deadline crunch is "unavoidable in pharma" — it is **avoidable here** by targeting *Quality Systems / CI* titles rather than *batch-release / audit-host* titles, where the crunch actually concentrates. To pivot fully into dedicated Process Improvement/OpEx she'll want a Six Sigma Green Belt + one or two documented DMAIC wins; entering via a Quality-Systems seat that carries CAPA/CI scope is the on-ramp. `[MED]`

### PATH C (BRIDGE / fastest paycheck) — Clinical Supply Chain leveled-up  ·  (or CDM if she wants the data-reasoning work)
Her **own lane is the warmest, fastest door back in** — clinical supply was relatively *insulated* during the downturn, and she can re-enter at **Sr Associate / Specialist II, not a reset**, at **$85–95k (Bay Area top-of-band)**. `[HIGH]` Use it as the immediate income floor and gap-closer, especially via contract/temp-to-hire. Its limitation is the reason it's the bridge and not the destination: **the clean IC track caps around $105–120k; reaching $150k means stepping onto a Manager rung** (though in clinical supply that rung is frequently light-management, not a big org). `[MED]` It's also the most **on-site/hybrid** option → transit-sensitive (hand to W4 for shuttle/BART analysis). *Alternative bridge:* **Clinical Data Management** is the better choice if she prioritizes the **"why/what-we-observed" data-reasoning** she named as energizing — CDM *proper* is reasoning-rich and has a **verified Principal-CDM IC path to ~$147k**, remote-friendly — but its entry tier carries rote data entry (her dislike), AI exposure, and database-lock crunch, so it's a stronger medium-term bet than a clean entry.

---

## 3. Explicit verdict on ClinOps

**ClinOps is a solid B, not the A — it is beaten by Regulatory Operations and Quality Systems for her, and it should not be the entry function.** Three hard-constraint failures:
1. **Entry comp is a pay cut.** The realistic ClinOps re-entry title is **CTA ($50–72k)** — *below* her ~$85k last salary and her $85–95k floor. `[MED]` Reg Ops, Quality, Supply, and CDM all clear the floor; ClinOps entry does not.
2. **The ladder engine is disqualified.** ClinOps reaches $150k mainly through **field CRA → Sr CRA III**, and **field CRA is ruled out by her no-car constraint + 28–32% burnout turnover** — a direct collision with WLB #1. `[HIGH]`
3. **Slower to $150k on a safe track.** The office-safe ClinOps roles (SSU, in-house CRA) top out ~$130–150k at Sr CRA after **6–10 years**, slower than the Principal-Specialist IC ladders in Reg Ops / Quality / CDM. `[MED]`

**The one ClinOps role worth keeping** is **Study Start-Up (SSU) Specialist** — a genuinely tight fit for her study-start-up + TMF + regulatory-document experience, and a fine **bridge** if Path A/B don't land quickly. But as a *lane*, ClinOps is second-tier for her. Do not default to it.

---

## 4. Sources (verified URLs)

**Macro / hiring health 2026**
- Fierce Biotech — layoffs easing Q2'26: https://www.fiercebiotech.com/biotech/biotechs-better-position-avoid-workforce-reductions-layoffs-continue-drop-q226
- Fierce Biotech Layoff Tracker 2026 / 2025: https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026 · https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025
- PharmaVoice / EY 2026 outlook: https://www.pharmavoice.com/news/layoffs-biopharma-2026-drug-pharma/810386/
- Fierce Biotech — early-stage funding slump: https://www.fiercebiotech.com/biotech/early-stage-funding-slumps-toward-post-pandemic-low-piling-more-pressure-biotech-startups
- Ropes & Gray — 2025 reset / 2026 outlook: https://www.ropesgray.com/en/insights/alerts/2026/03/from-volatility-to-vitality-how-2025-reset-the-life-sciences-market-and-whats-next-for-2026
- Xtalks — Biotech Hiring Trends 2026: https://xtalks.com/biotech-hiring-trends-2026-the-roles-companies-are-recruiting-for-now-4852/
- EPM Scientific — Life Sciences Careers 2026: https://www.epmscientific.com/en-us/industry-insights/career-advice/life-sciences-careers-2026-top-hiring-trends
- IntuitionLabs — Pharma/CRO layoffs 2025-26: https://intuitionlabs.ai/articles/pharma-cro-layoffs-2025-2026-analysis
- Business Standard / Parexel — clinical work to India: https://www.business-standard.com/amp/companies/news/global-pharma-shifting-high-value-clinical-research-work-to-india-parexel-126052201394_1.html
- IntuitionLabs — Pharma AI vendor landscape 2026: https://intuitionlabs.ai/articles/pharma-ai-vendor-landscape-2026
- ClinLab Staffing — contract-to-hire in life sciences: https://clinlabstaffing.com/the-rise-of-contract-to-hire-in-the-life-sciences-industry-is-it-right-for-your-company/

**Regulatory Affairs / Operations**
- Indeed — Veeva Vault RIM jobs: https://www.indeed.com/q-Veeva-Vault-Rim-jobs.html · ZipRecruiter: https://www.ziprecruiter.com/Jobs/Veeva-Vault-Rim
- Indeed — Veeva submissions specialist: https://www.indeed.com/q-veeva-submissions-specialist-jobs.html
- MasterControl — RA vs RegOps ("air traffic control tower"): https://www.mastercontrol.com/gxp-lifeline/regulatory-affairs-regulatory-operations-the-air-traffic-control-tower-of-life-sciences/
- dnxt — RA vs RegOps: https://www.dnxtsolutions.com/regulatory-affairs-vs-regulatory-operations/
- RAPS — RAC cert + eligibility (QA counts): https://www.raps.org/certifications/rac · https://raps.zendesk.com/hc/en-us/articles/19071915471629-What-is-the-RAC
- Salary.com — RA Specialist ladder: https://www1.salary.com/Regulatory-Affairs-Specialist-salaries.html · RegOps Specialist: https://www.salary.com/research/salary/recruiting/regulatory-operations-specialist-salary
- 6figr — Principal RA Specialist (IC): https://6figr.com/us/salary/principal-regulatory-affairs-specialist--t · ZipRecruiter: https://www.ziprecruiter.com/Salaries/Principal-Regulatory-Affairs-Specialist-Salary
- Veeva Careers — RIM roles (remote): https://careers.veeva.com/job/3aa2c21b-b9ec-4de9-aa7c-06523b8adb43/

**Quality Systems / Process Improvement**
- QA Resources — 2026 QA/QC talent gap: https://qaresources.com/the-2026-qa-qc-talent-gap-skills-pharma-employers-are-prioritising/ · in-demand QA skills: https://qaresources.com/the-most-in-demand-qa-skills-in-pharma-hiring-right-now/
- MasterControl — 2026 pharma quality trends: https://www.mastercontrol.com/resource-center/documents/2026-pharma-quality-trends-for-life-sciences/
- Prezent — top-paying biopharma jobs 2026 (Principal Scientist IC comp): https://www.prezent.ai/blog/top-paying-pharma-jobs
- Deel — IC-vs-management leveling / dual track: https://www.deel.com/blog/job-level-classification/
- OPEX Selection (Lean/OpEx recruiting): https://opexselection.com · ZipRecruiter Remote Lean Six Sigma: https://www.ziprecruiter.com/Jobs/Remote-Lean-Six-Sigma
- Scilife pharma audit (crunch): https://www.scilife.io/blog/pharma-audit

**Clinical Supply Chain / CMC**
- Salary.com — Clinical Supply Associate: https://www.salary.com/research/salary/listing/clinical-supply-associate-salary · Clinical Supply Manager: https://www.salary.com/research/salary/position/clinical-supply-manager-salary
- Scope Recruiting — 2026 supply chain market: https://www.scoperecruiting.com/blog/supply-chain-job-market-2026-job-seekers
- Artech — pharma roles 2026 (reshoring): https://www.artech.com/blog/pharmaceutical-careers-2026-key-roles-market-trends/
- N-SIDE — clinical trial supply resilience: https://www.n-side.com/en/insights/role-of-risk-management-in-building-resilient-clinical-trial-supply-chains/
- The Ladders — Sr Manager Investigational Supply Operations: https://www.theladders.com/job/senior-manager-investigational-supply-operations-aveo-oncology-boston-ma_87141127

**Clinical Data Management**
- Salary.com — Principal CDM (fetched, $147,437): https://www.salary.com/research/salary/position/principal-clinical-data-manager-salary
- Glassdoor — Clinical Data Manager: https://www.glassdoor.com/Salaries/clinical-data-manager-salary-SRCH_KO0,21.htm
- Indeed CDM jobs: https://www.indeed.com/q-clinical-data-manager-jobs.html · Recruiter.com declining-headcount view: https://www.recruiter.com/careers/clinical-data-managers/outlook/
- SCDM certs — CCDA / CCDM / CCDS: https://scdm.org/ccda-certification/ · https://scdm.org/ccdm-certification/ · https://scdm.org/ccds-certification/
- Applied Clinical Trials — CDM challenges / database lock: https://www.appliedclinicaltrialsonline.com/view/characterizing-clinical-data-management-challenges-and-their-impact
- Parexel — remote data-management jobs: https://jobs.parexel.com/en/employment/remote-data-management-jobs/877/6944/1000000000100/2

**Clinical Operations (CTA / CRA / SSU / CTM)**
- IntuitionLabs — entry-level CTA/IHCRA: https://intuitionlabs.ai/articles/entry-level-cta-ihcra-roles · CRA job-market 2025: https://intuitionlabs.ai/articles/cra-job-market-2025-outlook
- ACRP — CRA turnover study (28%/32%): https://acrpnet.org/2025/02/14/cra-turnover-within-contract-research-organizations-post-covid-19-a-cross-sectional-study
- Glassdoor — Clinical Trial Manager: https://www.glassdoor.com/Salaries/clinical-trial-manager-salary-SRCH_KO0,22.htm
- ZipRecruiter — Study Start-Up Specialist: https://www.ziprecruiter.com/Salaries/Study-Start-Up-Specialist-Salary · Syneos SSU careers: https://www.syneoshealth.com/clinical-corporate-careers/pages/study-start-up
- CCRPS — CTM career/salary roadmap: https://ccrps.org/clinical-research-blog/clinical-trial-manager-career-roadmap-essential-steps-and-salary-guide

**Medical / Regulatory Writing**
- AMWA — 2024 compensation report (reg-writing ~$166k): https://www.amwa.org/page/compensation_report
- RAPS — regulatory writing as a career entry: https://www.raps.org/resource/regulatory-writing-career-medical-pharma.html
- Glassdoor / ZipRecruiter — Principal Medical Writer: https://www.glassdoor.com/Salaries/principal-medical-writer-salary-SRCH_KO0,24.htm · https://www.ziprecruiter.com/Salaries/Principal-Medical-Writer-Salary
- UChicago — Regulatory Writing certificate: https://professional.uchicago.edu/find-your-fit/certificates/regulatory-writing

**Pharmacovigilance**
- IntuitionLabs — AI in pharmacovigilance: https://intuitionlabs.ai/articles/ai-pharmacovigilance-drug-safety
- Parexel — Drug Safety Associate qualifications: https://jobs.parexel.com/en/drug-safety-associate-qualifications-experience-and-skills
- Zamann Pharma — PV salary trends 2026: https://zamann-pharma.com/2026/05/04/pharmacovigilance-salary-in-year-global-pay-trends/

**Project / Program Management**
- PMI — Salary Survey 14th ed. (PMP premium): https://www.pmi.org/learning/careers/project-management-salary-survey
- Salary.com — Program Manager benchmark: https://www.salary.com/research/salary/benchmark/program-manager-salary
- Salary.com — Clinical Operations Project Manager: https://www.salary.com/research/salary/listing/clinical-operations-project-manager-salary
- Levels.fyi — Project Manager, SF Bay Area: https://www.levels.fyi/t/project-manager/locations/san-francisco-bay-area
- Built In — remote pharma PM: https://builtin.com/jobs/remote/project-management/pharmaceutical

> **Source-integrity note:** Glassdoor / ZipRecruiter / Indeed / Levels return HTTP 403 to automated fetchers, so their *figures* come from search-index snapshots (tagged `[MED]/[LOW]`); Salary.com, RAPS, AMWA, ACRP, SCDM, Fierce Biotech, PharmaVoice, and the IntuitionLabs articles were fetched and verified directly. Proprietary member salary surveys (RAPS, AMWA, PMI, DIA/SCDM) sit behind paywalls — cited figures come from published summaries, not raw member reports.

---

## Hand-offs to other workers
- **W2 (transferable/adjacent):** the Reg Ops / RIM angle leans hardest on her Veeva Author-level skill — please deep-dive Veeva RIM currency + RAC prep + Six Sigma Green Belt as the three highest-ROI upskilling moves.
- **W3 (WLB/rhythm):** validate the crunch profiles I flagged — filing-window (Reg Ops/Writing), database-lock (CDM), audit (Quality batch-release vs systems), study-start-up (Supply/SSU). My read: all are *cyclical/avoidable*, not chronic — please pressure-test.
- **W4 (geography/transit):** Clinical Supply is the most on-site/hybrid option (transit-sensitive); Reg Ops / Quality-systems / CDM / Medical Writing / PM are the most remote-friendly. Employer shuttles matter most for the Supply/on-site scenarios.